| Literature DB >> 35326412 |
Jen-Yang Tang1,2, Yuan-Bin Cheng3, Ya-Ting Chuang4, Kun-Han Yang5, Fang-Rong Chang5, Wangta Liu6, Hsueh-Wei Chang4,7.
Abstract
Oxidative stress and the AKT serine/threonine kinase (AKT) signaling pathway are essential regulators in cellular migration, metastasis, and angiogenesis. More than 300 withanolides were discovered from the plant family Solanaceae, exhibiting diverse functions. Notably, the relationship between oxidative stress, AKT signaling, and angiogenesis in withanolide treatments lacks comprehensive understanding. Here, we summarize connecting evidence related to oxidative stress, AKT signaling, and angiogenesis in the zebrafish model. A convenient vertebrate model monitored the in vivo effects of developmental and tumor xenograft angiogenesis using zebrafish embryos. The oxidative stress and AKT-signaling-modulating abilities of withanolides were highlighted in cancer treatments, which indicated that further assessments of their angiogenesis-modulating potential are necessary in the future. Moreover, targeting AKT for inhibiting AKT and its AKT signaling shows the potential for anti-migration and anti-angiogenesis purposes for future application to withanolides. This particularly holds for investigating the anti-angiogenetic effects mediated by the oxidative stress and AKT signaling pathways in withanolide-based cancer therapy in the future.Entities:
Keywords: AKT; angiogenesis; oxidative stress; withanolides; zebrafish
Mesh:
Substances:
Year: 2022 PMID: 35326412 PMCID: PMC8946239 DOI: 10.3390/cells11060961
Source DB: PubMed Journal: Cells ISSN: 2073-4409 Impact factor: 6.600
Figure 1Developmental angiogenesis stages and periods. (A) The embryos were subjected to analyses of intersegmental vessel (ISV) formation at 22–48 hpf, caudal vein plexus (CVP) at 25–48 hpf, subintestinal vessel (SIV) at 28–72 hpf, and hyaloid vessel (HV) at 2.5–30 dpf. (B) Representative images for different developmental stages. Tg (fli1: EGFP) zebrafish embryos were applied for observing the developmental angiogenesis for different stages. The red arrow indicates these structures.
Summary for the AKT-regulating–AKT-signaling network and modulating migration and angiogenesis.
| Drugs/Proteins | Activation | Inactivation | Migration Effects | Cells | References |
|---|---|---|---|---|---|
| ARP100, AG-L-66085 | MMP-2/9 | inhibit | retinoblastoma | [ | |
| Tanshinone IIA | AKT, MMP-9 | inhibit | aortic smooth muscle | [ | |
| siRNA eEF1A2 | AKT, MMP-9 | inhibit | pancreatic cancer | [ | |
| Paeonol | EMT | inhibit | pancreas cancer | [ | |
| Emodin | EMT | inhibit | colon cancer | [ | |
| MAPK | AKT | fibroblast, cancer | [ | ||
| POMx | MMP-2/9, EMT | inhibit | oral cancer | [ | |
| PDGF | AKT | promote | aortic smooth muscle | [ | |
| High glucose | AKT, VEGF-C | prostate cancer | [ | ||
| AKT | eNOS | endothelial cells | [ | ||
| EGF | AKT | promote | oral cancer | [ | |
| EGFR | EMT | breast cancer | [ | ||
| AKT | FOXO1 | prostate cancer | [ | ||
| circSTK40 | HSP90, AKT | breast cancer | [ | ||
| HSP90 | EMT | promote | colorectal cancer | [ | |
| PDK1 | Warburg effect | promote | lung cancer | [ | |
| High glycolysis | Warburg effect | angiogenesis | endothelial | [ | |
| MCT1 | Warburg effect | angiogenesis | endothelial | [ | |
| AKT | Warburg effect | cancer | [ | ||
| p38γ MAPK | Warburg effect | pancreatic cancer | [ | ||
| PDGF, AKT | Warburg effect | aortic smooth muscle | [ | ||
| F1,6BP, EGFR | Warburg effect | breast cancer | [ | ||
| NOS, HK2 | Warburg effect | ovarian cancer | [ | ||
| FOXO3a | Warburg effect | glioblastoma | [ | ||
| HIF-1α, VEGF | Warburg effect | lung cancer | [ | ||
| HSP90, PKM2 | Warburg effect | liver cancer | [ | ||
Figure 2AKT signaling network affects migration and angiogenesis. This flow chart summarizes Section 1, Section 2, Section 3, Section 4, Section 5, Section 6, Section 7 and Section 8.
Figure 3Structures for the selected withanolides mentioned in this review.
Withanolides exhibit antioxidant and/or pro-oxidant effects.
| Drugs | ROS | References |
|---|---|---|
| Coagulin-L | decrease | [ |
| Physalin B | decrease | [ |
| Coagulansin-A | decrease | [ |
| Withanone | decrease | [ |
| Tubocapsenolide A | increase | [ |
| Physapubenolide | increase | [ |
| Withanolide C | increase | [ |
| Physapruin A | increase | [ |
| 4β-Hydroxywithanolide E | increase | [ |
| Physalin A | decrease/increase | [ |
| Withaferin A | decrease/increase | [ |
Withanolides exhibit AKT inactivation and activation of cells.
| Drugs | AKT | Cells | References |
|---|---|---|---|
| Withaferin A | inactivation | head and neck cancer | [ |
| ovarian cancer | [ | ||
| lung cancer | [ | ||
| melanoma | [ | ||
| inactivation/activation | breast cancer | [ | |
| Tubocapsenolide A | inactivation | breast cancer | [ |
| Withametelin | inactivation | myeloid leukemia | [ |
| Coagulansin-A | inactivation | myeloid leukemia | [ |
| Daturataturin A | inactivation | keratinocytes | [ |
| Physapubenolide | inactivation | liver cancer | [ |
Withanolides that can regulate the AKT signaling pathway.
| Drugs | AKT Signaling | References |
|---|---|---|
| Withametelin | MAPK (ERK1/2) | [ |
| Coagulansin-A | ||
| Withaferin A | PDGF | [ |
| VEGF | [ | |
| FOXO3a | [ | |
| HSP90 | [ | |
| Peruvianolide B | NOS | [ |
| Peruvianolide C | ||
| Peruvianolide D | ||
| S5 | EGFR | [ |
| 3-Aziridinylwithaferin A | HSP90 | [ |
| Withanolide E | ||
| 4-Hydroxywithanolide E |
Figure 4Hypothesis: Withanolides affecting oxidative stress and AKT signaling may modulate angiogenesis, although this is rarely reported. Detailed investigation is warranted to examine the potential angiogenesis-modulating effects of withanolides in the future.